Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 4/20 | 0.37 |
| ▸ | NOS2 | P35228 | 2/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | PRCP | P42785 | 1/20 | 0.33 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1463295 | 0.83 | KDM1A (0.34) | MEN1KMT2ANPC1PRCP | |
| SCHEMBL18159761 | 0.73 | GRIN2B (0.33) | GRIN2B | |
| SCHEMBL1274980 | 0.73 | DDB1 (0.44) | NOS1GRIN2B | |
| SCHEMBL6168920 | 0.73 | ALDH1A1 (0.37) | NOS1NOS2GRIN2BMEN1KMT2A | |
| SCHEMBL3237381 | 0.71 | DDB1 (0.43) | NOS1NOS2SLC18A3 | |
| SCHEMBL7631291 | 0.71 | NOS1 (0.39) | NOS1NOS2GRIN2BPRCPSLC18A3 | |
| SCHEMBL15874659 | 0.71 | DDB1 (0.43) | NOS1NOS2SLC18A3 | |
| SCHEMBL618869 | 0.70 | MEN1 (0.44) | GRIN2BMEN1KMT2ANPC1PRCP | |
| SCHEMBL18150756 | 0.70 | KDM1A (0.34) | GRIN2B | |
| SCHEMBL6924404 | 0.66 | MEN1 (0.47) | MEN1KMT2APRCPSLC18A3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871760-B2 | [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871760-B2 | [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871760-B2 | [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2480545-A1 | FUSED TRIAZOLE AMINES AS P2X7 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| WO-2011033055-A1 | FUSED TRIAZOLE AMINES AS P2X7 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-24 | — | — | WO | disclosed |
| WO-2011033055-A1 | FUSED TRIAZOLE AMINES AS P2X7 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-24 | — | — | WO | disclosed |
| US-20110071143-A1 | FUSED TRIAZOLE AMINES AS P2X7 MODULATORS | BROTHERTON-PLEISS CHRISTINE E | 2011-03-24 | — | — | US | disclosed |
| US-20110071143-A1 | FUSED TRIAZOLE AMINES AS P2X7 MODULATORS | BROTHERTON-PLEISS CHRISTINE E | 2011-03-24 | — | — | US | disclosed |
| US-20110071143-A1 | FUSED TRIAZOLE AMINES AS P2X7 MODULATORS | BROTHERTON-PLEISS CHRISTINE E | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071143-A1 | FUSED TRIAZOLE AMINES AS P2X7 MODULATORS | P2RX3, P2RX7, P2RX1 | NOS1 2126/4885NOS2 2448/4885GRIN2B 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.